OIPE
MAR 2 7 2003
PATENT & TRADEMARK

$RCE #34
1644

Atty. Dkt. No. 018733-0884

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans J. HANSEN et al.

Title: USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING DIAGNOSIS AND THERAPY

RECEIVED
APR 0 1 2003
TECH CENTER 1600/2900

Appl. No.: 09/337,756

Appl. Filing Date: 06/22/1999

Examiner: D. Saunders

Art Unit: 1644

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Commissioner for Patents
Box RCE
Washington, D.C. 20231

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. This RCE and the enclosed items listed below are being filed prior to the earliest of: (1) payment of the issue fee (unless a petition under 37 C.F.R. § 1.313 is granted); (2) abandonment of the application; or (3) the filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. §141, or the commencement of a civil action under 35 U.S.C. §145 or §146 (unless the appeal or civil action is terminated).

1. Submission **required** under 37 C.F.R. §1.114: (check items that apply)

 a. Previously submitted:

 [**X**] Small Entity Status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

 b. Enclosed are:

 [**X**] Preliminary Amendment for RCE.

The filing fee is calculated below:

	Claims as Amended		Previously Paid For		Extra Claims Present		Rate		Fee Totals
RCE Fee 1.17(e)							$750.00		$750.00
Total Claims:	20	–	20	=	0	x	$18.00	=	$0.00

03/31/2003 AHONDAF1 00000044 09337756 375.00 OP
01 FC:2801

Independents:	3	—	3	=	0	x $84.00 =	$0.00
First presentation of any Multiple Dependent Claims:						+ $280.00 =	$0.00
						CLAIMS FEE TOTAL: =	$750.00

[] Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

[]	Extension for response filed within the first month:	$110.00	$0.00
[]	Extension for response filed within the second month:	$410.00	$0.00
[]	Extension for response filed within the third month:	$930.00	$0.00
[]	Extension for response filed within the fourth month:	$1,450.00	$0.00
[]	Extension for response filed within the fifth month:	$1,970.00	$0.00
		EXTENSION FEE TOTAL:	$0.00
		CLAIMS AND EXTENSION FEE TOTAL:	$750.00
[X]	Small Entity Fees Apply (subtract ½ of above):		$375.00
[]	Suspension of action requested under 37 C.F.R. § 1.103(c)		$0.00
		TOTAL FEE:	$375.00

[**X**] A check in the amount of $375.00 to cover the filing fee is enclosed.

[**X**] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date March 27, 2003

By _____

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

OIPE JC178
MAR 27 2003
PATENT & TRADEMARK OFFICE

Atty. Dkt. No. 018733-0942

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans J. HANSEN et al.

Title: USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING DIAGNOSIS AND THERAPY

RECEIVED
APR 0 1 2003
TECH CENTER 1600/2900

Prior Appl. No.: 09/337,756

Prior Appl. Filing Date: 06/22/1999

Examiner: D. Saunders

Art Unit: 1644

PRELIMINARY AMENDMENT FOR RCE

Commissioner for Patents
Box RCE
Washington, D.C. 20231

Sir:

Prior to further examination of the present application, Applicant respectfully requests that the following amended versions of the claims be entered into the record. A "Version with Markings to Show Changes Made" is appended.

In the Claims:

1. (Twice Amended) A method of treating diseased tissues in a patient, comprising:

D1

(A) administering to said patient a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate;

(B) optionally, administering to said patient a clearing composition, and allowing said composition to clear non-localized antibodies or antibody fragments from circulation;